soul trial oral semaglutide cardiovascular outcomes 2025 results Effects on in People With Overweight or Obesity (SELECT) rationale and design soul trial oral semaglutide cardiovascular – Oral Semaglutide and Cardiovascular Outcomes

Key findings: A March 2025 analytical report by supplement company Niagen Bioscience on 21 top-selling NAD supplements on Amazon revealed significant discrepancies between product claims and actual content: Only 24% met claims: Only 5 hard capsules contained NAD levels matching their labeled amounts

Oral GLP-1 Medications For those who prefer not to use injections, oral GLP-1 medications are another option, though they may not be as effective for significant weight loss

PMID 22403074

When retatrutide is licensed, prescribers will follow standard monitoring guidance

Nutrition on GLP-1 therapy Reduced appetite means every calorie counts more

Bigard, X